How not to evaluate whether psychosocial interventions benefit patients by Palmer, Steven C. et al.
  
 University of Groningen
How not to evaluate whether psychosocial interventions benefit patients





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2011
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Palmer, S. C., Schroevers, M. J., & Coyne, J. C. (2011). How not to evaluate whether psychosocial
interventions benefit patients. Psycho-oncology, 20(3), 337-338. https://doi.org/10.1002/pon.1919
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
Psycho-Oncology
Psycho-Oncology 20: 337–338 (2011)
Published online in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/pon.1919
Letter to the Editor




We had trouble recognizing Fors et al.’s [1]
systematic review from its depiction by Salander.
Despite a thorough eﬀort, Fors et al. identiﬁed
only 18 randomized controlled trails (RCTs)
evaluating psychosocial interventions for patients
with non-metastatic breast cancer meeting minimal
methodological standards and concluded that
‘insuﬃcient evidence exists to deﬁne optimal
psychoeducational interventions beyond an infor-
mation package that all cancer patients usually
receive, [or]yto determine the most beneﬁcial
social and emotional support interventions, even
though some subgroups with high initial cancer-
related stress seem to beneﬁt’. This stark evaluation
was all the more impressive, given the tendency
that we have noted [2,3] for some investigators to
hide essentially null primary results with secondary
and post hoc analyses so that interventions appear
eﬀective.
Salander identiﬁes serious problems in the
psycho-oncology literature, but undercuts his
credibility with overstatement. Rather than ‘few
people with cancer desire psychological treatment’
and ‘there seems to be no relationship between
psychological distress and desire for psychological
treatment’, a more accurate assessment is that
fewer cancer patients desire psychosocial interven-
tion than is widely assumed and that a positive
screening for distress is only a modestly eﬃcient
indicator of interest in psychosocial services [4]. One
implication of our assessment is that intervention
trials assuming that most cancer patients want
services will fail to meet accrual goals and could be
compromised methodologically by eﬀorts to accrue
suﬃcient numbers of patients. Another implication
is that reliance on screening positive for distress as
a means of gatekeeping for access to services will
likely deny services to patients who are motivated
and who might get substantial beneﬁts from
services, even if they could not register a decrease
in distress [4]. A ﬁnal implication is that many
cancer patients who volunteer for RCTs will not be
suﬃciently distressed to register a change in
distress. Indeed, post hoc analyses of null results
of a recent large trial of supportive expressive
group therapy for early breast cancer patients
showed that many of the groups did not have a
single distressed participant [5]. Investigators
designing an RCT for psychosocial services face
the dilemma of choosing between entry criteria that
yield patients representative of those who would
seek services versus criteria likely to yield a sample
capable of registering clinically signiﬁcant decreases
in distress. Moreover, given that many patients’
distress is driven by unmet needs that do not ﬁt
the standard model of emotional distress but
represent diverse issues such as pain, fatigue, and
ﬁnancial stress, we can ask whether distress is
particularly useful as a uniﬁed construct to target
for intervention.
Salander dramatizes stock criticisms of RCTs,
but provides an alternative that is worse than
RCTs for evaluating whether there is beneﬁt to
intervention. First, it is probably true that RCTs
do not attract representative cancer patients, but
oﬀering free psychosocial treatment in an RCT
may attract patients representative of those who
would seek treatment if these interventions were
oﬀered under conditions of routine care.
Second, Salander’s proposal to replace RCTs
with quasi-experimental comparisons of patients
who seek and receive psychosocial intervention
versus those who did not want treatment would be
doomed to yield very diﬀerent groups of patients
and so would not be readily interpretable. The
infamous evaluation of the Bristol Cancer Help
Centre (BCHC) adopted something similar to
Salander’s proposed design with disastrous eﬀects
[6]. BCHC staﬀ were so conﬁdent of the beneﬁts of
their services and that patients preferred them that
they deemed an RCT unethical. Instead, a non-
randomized design was implemented comparing
cancer patients choosing to attend the BCHC to
those treated in conventional cancer treatment
settings. Published results initially reported that
BCHC patients had signiﬁcantly worse survival
than controls. Although this was most likely a
result of sicker patients seeking treatments at
BCHC, publicity generated by these results severely
damaged the credibility of the BCHC and more
generally set back the cause of psychosocial
intervention in the UK.
We agree with some of Salander’s points, but
believe that important considerations are over-
looked. For example, it seems unlikely that a
substantial number of patients entered into RCTs
are uninterested in services—such patients would
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vote with their feet before or during the consent
process. Yet we need to ask the sobering question
of why we cannot give away psychosocial inter-
ventions in clinical trials, and we need to plan
much more realistically for not being able to attract
most patients to trials. Similarly, we believe there
is a role for designs accommodating patient
preference and focusing on generalizability without
harming internal validity [7]. We do not, however,
see Salander’s model as such an improvement.
It would not provide credible evidence of beneﬁt to
cancer patients or garner the support needed to
ensure that psychosocial services are available and
reimbursable.
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